Accuracy of rapid point-of-care antigen-based diagnostics for SARS-CoV-2: an updated systematic review and meta-analysis with meta regression analyzing influencing factors
Authors:
- Lukas E. BrümmerLBLukas E. Brümmer
- Stephan KatzenschlagerSKStephan Katzenschlager
- Sean McGrathSMSean McGrath
- Stephani SchmitzSSStephani Schmitz
- Mary GaeddertMGMary Gaeddert
- Christian ErdmannCEChristian Erdmann
- Marc BotaMBMarc Bota
- Maurizio GrilliMGMaurizio Grilli
- Jan LarmannJan Larmann
- Markus A. WeigandMWMarkus A. Weigand
- Nira R. PollockNPNira R. Pollock
- Aurélien MacéAMAurélien Macé
Preprint
Abstract
Background Comprehensive information about the accuracy of antigen rapid diagnostic tests (Ag-RDTs) for SARS-CoV-2 is essential to guide public health decision makers in choosing the best tests and testing policies. In August 2021, we published a systematic review and meta-analysis about the accuracy of Ag-RDTs. We now update this work and analyze the factors influencing test sensitivity in further detail. Methods and findings We registered the review on PROSPERO (registration number: CRD42020225140). We systematically searched multiple databases (PubMed, Web of Science Core Collection, medRvix, bioRvix, and FIND) for publications evaluating the accuracy of Ag-RDTs for SARS-CoV-2 until August 31, 2021. Descriptive analyses of all studies were performed, and when more than 4 studies were available, a random-effects meta-analysis was used to estimate pooled sensitivity and specificity with reverse transcription polymerase chain reaction (RT-PCR) testing as a reference. To evaluate factors influencing test sensitivity, we performed 3 different analyses using multivariate mixed-effects meta-regression models. We included 194 studies with 221,878 Ag-RDTs performed. Overall, the pooled estimates of Ag-RDT sensitivity and specificity were 72.0% (95% confidence interval [CI] 69.8 to 74.2) and 98.9% (95% CI 98.6 to 99.1), respectively. When manufacturer instructions were followed, sensitivity increased to 76.4% (95%CI 73.8 to 78.8). Sensitivity was markedly better on samples with lower RT-PCR cycle threshold (Ct) values (sensitivity of 97.9% [95% CI 96.9 to 98.9] and 90.6% [95% CI 88.3 to 93.0] for Ct-values <20 and 90%). With viral load, as estimated by Ct-value, being the most influential factor on their sensitivity, they are especially useful to detect persons with high viral load who are most likely to transmit the virus. To further quantify the effects of other factors influencing test sensitivity, standardization of clinical accuracy studies and access to patient level Ct-values and duration of symptoms are needed.Keywords
All Related Versions
- Published version: PLOS Medicine, 19 (5), e1004011.
This publication has 173 references indexed in Scilit:
- Performance of a novel diagnostic assay for rapid SARS-CoV-2 antigen detection in nasopharynx samplesClinical Microbiology and Infection, 2021
- Panbio antigen rapid test is reliable to diagnose SARS-CoV-2 infection in the first 7 days after the onset of symptomsJournal of Clinical Virology, 2020
- Rethinking Covid-19 Test Sensitivity — A Strategy for ContainmentNew England Journal of Medicine, 2020
- Urgent need of rapid tests for SARS CoV-2 antigen detection: Evaluation of the SD-Biosensor antigen test for SARS-CoV-2Journal of Clinical Virology, 2020
- Antigen-based testing but not real-time PCR correlates with SARS-CoV-2 virus culturemedRxiv, 2020
- Evaluation of the accuracy, ease of use and limit of detection of novel, rapid, antigen-detecting point-of-care diagnostics for SARS-CoV-2medRxiv, 2020
- Evaluation of a novel antigen-based rapid detection test for the diagnosis of SARS-CoV-2 in respiratory samplesInternational Journal of Infectious Diseases, 2020
- Testing Healthcare Workers Exposed to COVID19 using Rapid Antigen DetectionmedRxiv, 2020
- Low performance of rapid antigen detection test as frontline testing for COVID-19 diagnosisJournal of Clinical Virology, 2020
- SARS-CoV-2 qRT-PCR Ct value distribution in Japan and possible utility of rapid antigen testing kitmedRxiv, 2020